Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gendicine plus radiotherapy for advanced nasopharyngeal carcinoma
ChiCTR-TRC-08000092Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2001
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rAdp53 in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Local-regional recurrence and Survival rate. Started Oct 2001; status: completed.
02
Drugs
rAdp53
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR-TRC-08000092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-08000092.